NEW YORK, March 20, 2018 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Proteostasis Therapeutics, Inc. ("Proteostasis" or the "Company") (NASDAQ: PTI). Such investors are encouraged to obtain additional information and assist the investigation by visiting the firm's site: www.bgandg.com/pti.
The investigation concerns whether Proteostasis and certain of its officers and/or directors have violated Federal Securities Laws.
On March 20, 2018, Kerrisdale Capital Management published a report entitled "Proteostasis Therapeutics, Inc.: Hyped-Up Lung Data? Just a Lot of Hot Air." The report asserted that in the Phase 2 study for the Company's cystic-fibrosis drug, PTI-428, "the placebo group's small size and anomalously bad outcomes misleadingly make the treatment group's unimpressive results look good by comparison." Accordingly, the report concluded that the drug "is ineffective and will likely fail future Phase 3 trials." On this news, Proteostasis's share price has fallen sharply during intraday trading on March 20, 2018.
If you are aware of any facts relating to this investigation, or purchased Proteostasis shares, you can assist this investigation by visiting the firm's site: www.bgandg.com/pti. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | email@example.com
SOURCE Bronstein, Gewirtz & Grossman, LLC